For about one-third of people with psoriasis, the red, scaly patches first show up in childhood, which means it’s often parents doing the research on how to help. In a phase 3 study published in the British Journal of Dermatology and reported by Dermatology Times, researchers tested Skyrizi, a biologic shot many adults already use, in children and teens with moderate to severe plaque psoriasis, and the results give parents a clearer picture of what treatment can do.
The study followed 137 patients between ages 6 and 17. Teens ages 12 to 17 were randomly assigned to Skyrizi or Stelara, an older biologic, and after 16 weeks, 41 percent of the Skyrizi group had completely clear skin compared with 18 percent of the Stelara group. Most teens on either drug saw their skin get at least 90 percent clearer, at 65 percent for Skyrizi and 61 percent for Stelara. The researchers didn’t run formal statistical tests between the two drugs and the groups were small, so that head-to-head gap isn’t conclusive.
Younger kids ages 6 to 11 all received Skyrizi, in a small group of 30 children, and their numbers were similarly encouraging. By week 16, 90 percent had clear or almost clear skin, 77 percent were at least 90 percent clearer and 43 percent were completely clear. Teens also reported less itching and said psoriasis got in the way of daily life less, with those improvements still there at the one-year mark. Skyrizi works by blocking IL-23, one of the immune signals that fuels the inflammation behind psoriasis plaques.
Another part of the study looked at teens who were doing well and then came off the drug. Many of them had a flare, but restarting the shots brought their improvement back. For families weighing a biologic, it’s a reminder that psoriasis is a long-term condition and finding the right treatment can take some patience.
Side effects in kids and teens lined up with what’s been seen in adults, with no new safety concerns. In the study, the most common side effects were colds (nasopharyngitis) in about 30 percent of teens and fever in about 13 percent of younger kids, and longer-term monitoring remains important for younger patients.
The FDA approved Skyrizi in June for children 6 and older with moderate to severe plaque psoriasis who are candidates for systemic treatment or light therapy, along with a smaller-dose syringe for kids under about 88 pounds. After two starter doses four weeks apart, it’s given once every 12 weeks. If your child’s psoriasis isn’t improving with creams, ask a board-certified dermatologist whether a biologic makes sense, and our guide to psoriasis treatment options is a helpful place to start before that appointment.
















